We would love to hear your thoughts about our site and services, please take our survey here.
Hi EE,
I think Chester is reading this correctly. In order for the value of a novel drug to be realised Scancell need to prove them beyond any reasonable doubt over time. I am afraid that there is no shortcut but that does not mean there is no monetary value in this; whilst there may be trading opportunities as results are released, deals will come towards the end when Scancell have done all the donkey work.
Remember what Scancell are doing here: proving the utility and long term benefit of novel drugs. That is the game for Scancell and it is the same game for all pharma big or small. So if big pharma know the game why would they jump in early days? A collaboration yes, a buyout eventually.
ATB
Only news required is funding and this will do 50 to 100% even if diluted imo
CW,
Sometimes I do not think it would matter what you post as some people are just going to react in the same way. Like a jerk reaction. I do not think you need explain yourself to anybody. Just carry on posting and people will see the merits or not.
ATB.
Bantham,
The aim of translational research is to move promising scientific discoveries into actual treatments that benefit patients. Just my opinion but this is exactly where Parsortix is at. You can put your own spin on it of course.
For those that have a medium to long term outlook. IMO
Ruck,
Your 10.06. Why do I have flashbacks to Hansel & Gretel when reading your post? You do know that the Witch did get pushed into her own oven and died before she could fatten up and eat her victims.
Or have I got the wrong end of the stick again :)
The beauty of any question is that when answered it usually is helpful none the less. So re delivery method I doubt a private investor would think to ask that or at least not be the first question. I do agree though that analysts should have done their research, if anything sounded a bit lazy to me. But the net situation is that all people tuning into Scancell for the first time not only can see excellent results but also appreciate that they use an excellent delivery method. Maybe that analyst was a SCLP fan in disguise and was acting daft? Was it Panmure? They know us very well.
Thanks Bermuda and Ray. Great knowledge. I can always read and understand your posts which is testament to how well worded they are.
Krafty the best questions elicit the most useful answers!! Thanks.
Re: LD, she is naughty isn’t she! Often saying things like I cannot say anymore and that is as much science as I am aloud! Gives one the impression that there is much more to be said, and of course there is but the levels of complexity are mind boggling.
GF,
Some people hand over control to others (often unknowingly), some people take it (instinctively). Others that are astute do not get involved in such games and concentrate on bigger and more important things. What we witness on these bulletin boards on a daily basis is a power struggle between those that are not focused on the bigger and more important things imo.
Yes Crumbs, you have played a part in my better understanding of Scancell. Genuinely much appreciated. You have a depth of knowledge of this company that I will not even try to aspire too. However I have got a good handle on this share now so whilst I am happy to read and appreciate your post's I do not need to hang out of your coat tails any longer. That said I think this bulletin board is a better place for having you so I would certainly like to see you back like straight away. If I may offer a bit of advice... When people are throwing rocks at you just duck! They will soon run out of rocks (unless you throw them back) and get board. Also it would be a good example to set by moving on. The Modi thing was just a blip as the share price has borne out.
Ruck, according to RG, LD delved into a deep pile of scientific papers on that plane to the USA. Who else on this board reads scientific papers do you think? To gain an unrivalled knowledge might have read everything and anything? Which posters do you think? Yet CW is targeted for doing the same? By posters that ain’t that scientific it seems
C11,
So you would value these, "relevant and helpful posts," above clinical trial evidence as communicated yesterday? Above peer reviewed articles, an RNS communicating for instance - a new delivery method, a research/broker note?
EE mentioned yesterday that we will see where this is at over the coming weeks.
I think with Milan, the trial protocol being amended to accommodate ISCIB1+ and just the fact the market needs to digest these fine SCOPE results that is a fair comment.
I do look at Avacta and wonder why we are not around the same share price. Are they overvalued, are we undervalued. Probably a bit if both. Anyways, facts and data will drive this. Scancell are doing their part. Should be a steady ride from here imo.
Never in doubt!
The danger for non scientific types like me is that it is hard to asses progress data and what it means going forward. However, I think it is safe to say that this data is highly encouraging and most importantly is shown to work over a period of time. Noted that patient 9 in the spider graph (slide no6) was the only patient PR section (10 patients) that saw the tumor shrink, grow, and then overall shrinkage.